PE20211197A1 - OLIGONUCLEOTIDES TO MODULATE THE EXPRESSION OF TMEM106B - Google Patents

OLIGONUCLEOTIDES TO MODULATE THE EXPRESSION OF TMEM106B

Info

Publication number
PE20211197A1
PE20211197A1 PE2020001186A PE2020001186A PE20211197A1 PE 20211197 A1 PE20211197 A1 PE 20211197A1 PE 2020001186 A PE2020001186 A PE 2020001186A PE 2020001186 A PE2020001186 A PE 2020001186A PE 20211197 A1 PE20211197 A1 PE 20211197A1
Authority
PE
Peru
Prior art keywords
oligonucleotide
nucleotides
tmem106b
oligonucleotides
modulate
Prior art date
Application number
PE2020001186A
Other languages
Spanish (es)
Inventor
Peter Hagedorn
Marianne L Jensen
Lukasz Kielpinski
Amy Easton
Benny Chih
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20211197A1 publication Critical patent/PE20211197A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Abstract

SE REFIERE A UN OLIGONUCLEOTIDO ANTISENTIDO MONOCATENARIO DE 10 A 50 NUCLEOTIDOS DE LONGITUD, QUE COMPRENDE UNA SECUENCIA DE NUCLEOTIDOS CONTIGUOS DE 10 A 30 NUCLEOTIDOS DE LONGITUD QUE ES AL MENOS 90 % COMPLEMENTARIO DE UN ACIDO NUCLEICO DIANA DE LA PROTEINA TRANSMEMBRANA 106B DE MAMIFERO (TMEM106B); EN DONDE EL OLIGONUCLEOTIDO ES UN siARN O shARN O FORMA LA CADENA GUIA DE UN COMPLEJO DE siARN O shARN. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO OLIGONUCLEOTIDO QUE ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS COMO DEGENERACION LOBULAR FRONTOTEMPORAL (FTLD), ENFERMEDAD DE PARKINSON, LEUCODISTROFIAS HIPOMIELINIZANTES, ENFERMEDAD DE ALZHEIMER.REFERS TO A MONOCATENARY ANTI-SENSE OLIGONUCLEOTIDE OF 10 TO 50 NUCLEOTIDES IN LENGTH, WHICH INCLUDES A SEQUENCE OF CONTIGUOUS NUCLEOTIDES OF 10 TO 30 NUCLEOTIDES IN LENGTH WHICH IS AT LEAST 90% COMPLEMENTARY OF AN ACIMENDUM NUCLEOTIDE 10 TM OF 10 ); WHERE THE OLIGONUCLEOTIDE IS A siARN OR shARN OR IT FORMS THE GUIDE CHAIN OF A siRNA OR shARN COMPLEX. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES SAID OLIGONUCLEOTIDE THAT IS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS FRONTOTEMPORAL LOBULAR DEGENERATION (FTLD), PARKINSON'S DISEASE, ALLEYPODYCODYSTROPHY, LEIPODYCODISTROPHY, LEIPODYCODISTROPHY, AND PARKINSON'S DISEASE.

PE2020001186A 2018-02-09 2019-02-08 OLIGONUCLEOTIDES TO MODULATE THE EXPRESSION OF TMEM106B PE20211197A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18156142 2018-02-09
US201862669251P 2018-05-09 2018-05-09
PCT/EP2019/053116 WO2019154979A1 (en) 2018-02-09 2019-02-08 Oligonucleotides for modulating tmem106b expression

Publications (1)

Publication Number Publication Date
PE20211197A1 true PE20211197A1 (en) 2021-07-01

Family

ID=65433647

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001186A PE20211197A1 (en) 2018-02-09 2019-02-08 OLIGONUCLEOTIDES TO MODULATE THE EXPRESSION OF TMEM106B

Country Status (17)

Country Link
US (1) US11485975B2 (en)
EP (1) EP3749766A1 (en)
JP (1) JP7281474B2 (en)
KR (1) KR20200108315A (en)
CN (1) CN111868245A (en)
AU (1) AU2019219194A1 (en)
BR (1) BR112020016170A2 (en)
CA (1) CA3088071A1 (en)
CL (1) CL2020002038A1 (en)
CR (1) CR20200346A (en)
IL (1) IL276357A (en)
MA (1) MA51795A (en)
MX (1) MX2020008290A (en)
PE (1) PE20211197A1 (en)
RU (1) RU2020125769A (en)
SG (1) SG11202007093YA (en)
WO (1) WO2019154979A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4058152A1 (en) * 2019-11-14 2022-09-21 The Board of Regents of the University of Oklahoma Oligonucleotide interference treatments of prostate cancer
JP2023527684A (en) * 2020-05-11 2023-06-30 ジェネンテック， インコーポレイテッド Complement component C1S inhibitors for treating neurological disorders and related compositions, systems and methods of using same
WO2023141507A1 (en) * 2022-01-20 2023-07-27 Genentech, Inc. Antisense oligonucleotides for modulating tmem106b expression

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
EP2341057A3 (en) 1997-09-12 2011-11-23 Exiqon A/S Oligonucleotide Analogues
AU758956B2 (en) 1999-02-12 2003-04-03 Daiichi Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues
EP1178999B1 (en) 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
DK2813582T3 (en) 2000-12-01 2017-07-31 Max-Planck-Gesellschaft Zur Förderung Der Wss E V Small RNA molecules that mediate RNA interference
EP1414840A4 (en) 2001-03-27 2005-04-13 Univ Delaware Genomics applications for modified oligonucleotides
CA2453183C (en) 2001-07-12 2016-05-10 University Of Massachusetts In vivo production of small interfering rnas that mediate gene silencing
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
AU2003281969B2 (en) 2002-11-18 2011-01-27 Roche Innovation Center Copenhagen A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
WO2004083430A2 (en) 2003-03-21 2004-09-30 Santaris Pharma A/S SHORT INTERFERING RNA (siRNA) ANALOGUES
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
US7919472B2 (en) 2004-09-17 2011-04-05 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
EA015563B1 (en) 2006-03-23 2011-08-30 Сантарис Фарма А/С Small internally segmented interfering rna
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
ES2389737T3 (en) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. 5 'modified bicyclic nucleic acid analogs
US9550988B2 (en) 2006-10-18 2017-01-24 Ionis Pharmaceuticals, Inc. Antisense compounds
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
JP5855463B2 (en) 2008-12-18 2016-02-09 ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Extended DICER substrate drugs and methods for specific inhibition of gene expression
JP5879256B2 (en) 2009-05-02 2016-03-08 ジェンザイム・コーポレーション Gene therapy for neurodegenerative disorders
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2580326A1 (en) 2010-06-11 2013-04-17 Antisense Pharma GmbH Method for selective oligonucleotide modification
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP3467109A1 (en) 2011-02-08 2019-04-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
RU2013150331A (en) 2011-04-20 2015-05-27 Рош Гликарт Аг METHOD AND DEVICES FOR A pH-DEPENDENT PASSAGE OF A HEMATOENCEPHALIC BARRIER
DK2742136T3 (en) 2011-08-11 2017-11-20 Ionis Pharmaceuticals Inc GAPMER COMPOUNDS INCLUDING 5 'MODIFIED DEOXYRIBONUCLEOSIDES IN GAP AND APPLICATIONS THEREOF
US9221864B2 (en) 2012-04-09 2015-12-29 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
KR20160074368A (en) 2012-05-16 2016-06-28 라나 테라퓨틱스, 인크. Compositions and methods for modulating utrn expression
JP2015523855A (en) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Compositions and methods for modulating APOA1 and ABCA1 expression
EP2850184A4 (en) 2012-05-16 2016-01-27 Rana Therapeutics Inc Compositions and methods for modulating gene expression
EP2920304B1 (en) 2012-11-15 2019-03-06 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
KR102287532B1 (en) 2014-01-30 2021-08-11 에프. 호프만-라 로슈 아게 Poly oligomer compound with biocleavable conjugates
US20150231151A1 (en) 2014-02-19 2015-08-20 University Of Houston System Compositions and methods for the treatment of neurodegenerative diseases
CN104450621B (en) * 2014-09-30 2018-10-19 首都医科大学附属北京口腔医院 WDR63 genes are in mescenchymal stem cell bone to the regulation and control method with tooth into atomization
SG11201706293XA (en) * 2015-02-04 2017-09-28 Hoffmann La Roche Tau antisense oligomers and uses thereof
US20180023081A1 (en) * 2015-02-04 2018-01-25 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks

Also Published As

Publication number Publication date
KR20200108315A (en) 2020-09-17
WO2019154979A1 (en) 2019-08-15
CN111868245A (en) 2020-10-30
CR20200346A (en) 2020-10-19
US20210054383A1 (en) 2021-02-25
IL276357A (en) 2020-09-30
CA3088071A1 (en) 2019-08-15
JP2021514182A (en) 2021-06-10
JP7281474B2 (en) 2023-05-25
AU2019219194A1 (en) 2020-08-06
BR112020016170A2 (en) 2020-12-15
US11485975B2 (en) 2022-11-01
RU2020125769A (en) 2022-03-10
RU2020125769A3 (en) 2022-03-10
SG11202007093YA (en) 2020-08-28
MX2020008290A (en) 2020-09-25
EP3749766A1 (en) 2020-12-16
MA51795A (en) 2020-12-16
CL2020002038A1 (en) 2020-10-23

Similar Documents

Publication Publication Date Title
CY1123289T1 (en) OLIGONUCLEOTIDE COMPOUNDS FOR TARGETING HUNTINGTIN mRNA
PE20171766A1 (en) ANTI-SENSE OLIGOMERS OF TAU AND USES OF THEM
PE20211197A1 (en) OLIGONUCLEOTIDES TO MODULATE THE EXPRESSION OF TMEM106B
BR112019005548A2 (en) treatment of huntington's disease with aav
PE20201499A1 (en) OLIGONUCLEOTIDES TO REDUCE THE EXPRESSION OF PD-L1
BR112017013597A2 (en) nucleic acid molecule, pharmaceutical composition, vector or cell, and method for treating a disease.
NZ730296A (en) Modified double-stranded rna agents
EP4219713A3 (en) Products and compositions
UY36126A (en) ? 6,8-DIOXABICICLO COMPOUNDS [3.2.1] OCTANO-2,3-DIOL REPLACED AS ADDRESS AGENTS TO ASGPR ?.
PE20191047A1 (en) COMPOUNDS AND METHODS TO REDUCE THE EXPRESSION OF ATXN3
EA201591281A1 (en) RIBONUCLEIC ACIDS WITH 4'-THIOMODIFIED NUCLEOTIDES AND RELATED METHODS
AR081993A1 (en) TREATMENT OF DISEASES RELATED TO THE SUBUNITY TO REGULATED BY VOLTAGE OF THE SODIUM CHANNEL (SCNA) BY INHIBITION OF THE SCNA ANTISENTIDO NATURAL TRANSCRIPT
PE20190381A1 (en) ANTI-SENSE OLIGONUCLEOTIDES TO MODULATE THE EXPRESSION OF HTRA1
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
PE20210518A1 (en) COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF LRRK2
EA201790789A1 (en) COMPOSITIONS AND METHODS DESIGNED TO INHIBIT EXPRESSION OF THE HAO1 GENE (OXIDASE 1 HYDROXYLIC ACIDS (GLYCOLATE OXIDASE))
MX2014014902A (en) Compositions comprising apomorphine and organic acids and uses thereof.
BR112016022742A2 (en) compositions and methods for modulating growth hormone receptor expression
ECSP10010637A (en) ANTI-FACTOR D HUMANIZED ANTIBODIES AND THEIR USES
CL2020001742A1 (en) Glycolate oxidase inhibitors for the treatment of diseases
PE20190626A1 (en) COMPOSITIONS AND METHODS TO MODULATE THE EXPRESSION OF FACTOR B OF THE COMPLEMENT
PE20181448A1 (en) COMPOSITIONS AND METHODS TO REDUCE THE EXPRESSION OF TAU
CL2018003044A1 (en) 6-aminopyridine-3-yl thiazoles as ror modulators.
CL2017001042A1 (en) Trifluoromethyl alcohols as roryt modulators
SV2017005354A (en) QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS